Cellular topoisomerase activates inflammatory gene expression during SARS-CoV-2 infection. Topoisomerase inhibitor Topotecan is a FDA-approved drug, and suppresses the over-expression of inflammatory genes. The medical efficacy of Topotecan therapy against SARS-CoV-2 infection was demonstrated by using virus-infected hamster and hACE2 Tg mouse models. The reduced genes during the treatment of Topotecan were consistent with those were intrinsically activated in the lung autopsy from COVID-19 victims.
No comments:
Post a Comment